Content about Jeremy Levin

October 30, 2013

Teva Pharmaceutical Industries' president and CEO has stepped down, the Israeli drug maker said.

JERUSALEM — Teva Pharmaceutical Industries' president and CEO has stepped down, the Israeli drug maker said.

Teva announced the resignation of Jeremy Levin and that the board of directors had named EVP and CFO Eyal Desheh as interim president and CEO. Desheh has worked at Teva for more than 12 years, serving as CFO for the last five.

November 6, 2012

Teva Pharmaceutical Industries has made a few new executive appointments, the drug maker said Tuesday.

JERUSALEM — Teva Pharmaceutical Industries has made some new executive appointments, the drug maker said Tuesday.

Teva promoted Allan Oberman, currently SVP North America generic pharmaceuticals, to president and CEO of Teva Americas Generics. In the new role, Oberman will report directly to Teva president and CEO Jeremy Levin and have continued responsibility for generics in the North American market and overall management of the company's Latin American businesses.

August 2, 2012

Teva Pharmaceutical Industries has named Carlo De Notaristefani as president and CEO of global operations and Aharon "Arik" Yaari as EVP community and institutional affairs, the Israeli drug maker said Thursday.

JERUSALEM — Teva Pharmaceutical Industries has named Carlo De Notaristefani as president and CEO of global operations and Aharon "Arik" Yaari as EVP community and institutional affairs, the Israeli drug maker said Thursday.

The company said De Notaristefani and Yaari would report directly to Teva president and CEO Jeremy Levin.

January 23, 2012

The Food and Drug Administration is streamlining the enrollment process for risk evaluation and mitigation strategies for a class of painkillers, the agency said.

SUPPLIER NEWS — The Food and Drug Administration is streamlining the enrollment process for risk evaluation and mitigation strategies for a class of painkillers, the agency said. The FDA announced the approval of a single REMS for transmucosal immediate-release fentanyl drugs. The new system, which takes effect in March, will allow prescribers and pharmacies to enroll into one system instead of individual systems for each product.